멀티플렉스 PCR 패널 검사 시장 규모, 점유율 및 동향 분석 보고서 : 질환별, 검사 환경별, 처리 능력별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Multiplex PCR Panel Testing Market Summary

The global multiplex PCR panel testing market size was estimated at USD 2.58 billion in 2025 and is projected to reach USD 4.86 billion by 2033, registering a CAGR of 8.42% from 2026 to 2033. The market growth is driven by the growing prevalence of respiratory and gastrointestinal infections and strong demand for rapid syndromic testing in infectious disease diagnostics.

Moreover, advancements in multiplexing technologies, laboratory automation, and high-throughput molecular workflows are supporting broader adoption of multiplex PCR panels across healthcare settings. Expanding utilization of decentralized and point-of-care molecular diagnostic platforms is further contributing to market growth.

The rising prevalence of respiratory and gastrointestinal infections is driving market growth due to growing demand for rapid and accurate pathogen identification. Multiplex PCR panel enables simultaneous detection of multiple viral, bacterial, and parasitic pathogens from a single sample, making them well-suited for managing infections associated with overlapping clinical symptoms. The growing incidence of respiratory infections, including influenza, RSV, pneumonia, and other lower respiratory tract infections, along with outbreaks of gastrointestinal infections such as norovirus and Shigella, is accelerating the adoption of syndromic molecular diagnostics across hospitals and clinical laboratories. According to a study published in The Lancet in September 2024, Global Burden of Disease analyses estimated that lower respiratory infections accounted for approximately 344 million cases globally and continued to rank among the leading infectious causes of mortality worldwide. Moreover, the Centers for Disease Control and Prevention reported in April 2026 that nearly 2,500 norovirus outbreaks occur annually in the U.S., while norovirus continues to cause approximately 685 million cases of acute gastroenteritis globally each year.

The growing demand for rapid syndromic testing in infectious disease diagnostics is supporting market growth due to the need for faster and more comprehensive pathogen detection. Syndromic multiplex PCR panel enables simultaneous identification of multiple pathogens associated with similar clinical symptoms from a single patient sample, reducing diagnostic turnaround time compared with conventional culture-based and single-target testing methods. Healthcare providers are adopting rapid syndromic testing to improve early diagnosis, patient triage, infection control, and treatment selection, particularly in respiratory, gastrointestinal, bloodstream, and central nervous system infections. The growing clinical emphasis on antimicrobial stewardship and reduction of unnecessary antibiotic use is further supporting the adoption of multiplex syndromic molecular diagnostics across hospitals, emergency departments, and clinical laboratories.

Continuous advancements in multiplexing and laboratory automation technologies are driving market growth by improving testing efficiency, workflow automation, and diagnostic accuracy. Innovations in high-plex assay development, automated sample preparation, integrated molecular systems, and real-time data analysis are enabling simultaneous detection of multiple pathogens with faster turnaround times and minimal hands-on time. These technologies also support higher laboratory throughput and improved operational efficiency in clinical settings. For instance, in January 2026, Cepheid received U.S. FDA clearance for the Xpert GI Panel, a multiplex PCR assay designed for simultaneous detection of 11 gastrointestinal bacterial, viral, and parasitic pathogens from a single stool sample. The panel utilizes Cepheid's 10-color multiplexing technology on GeneXpert systems, supporting rapid syndromic testing and automated molecular diagnostic workflows.

Global Multiplex PCR Panel Testing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global multiplex PCR panel testing market report based on disease application, end use, throughput, testing setting, and region:

• Disease Application Outlook (Revenue, USD Million, 2021 - 2033)
• Respiratory Panel
• Gastrointestinal Panel
• Sexually Transmitted Infection (STI) Panel
• Bloodstream / Sepsis Panel
• Central Nervous System (CNS) Panel
• Tropical Disease Panel
• Other Panel
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals & Clinics (dominant)
• Diagnostic Laboratories (central labs)
• Ambulatory Care Centers
• Academic & Research Institutes
• Public Health Laboratories
• Physician Office Labs (POLs)
• Point-of-Care Settings
• Testing Setting Outlook (Revenue, USD Million, 2021 - 2033)
• Centralized Laboratory Testing
• Near-Patient Testing
• Others
• Throughput Outlook (Revenue, USD Million, 2021 - 2033)
• Low-throughput systems (POC)
• Medium-throughput systems
• High-throughput lab systems
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Disease Application
  • 1.2.2. End Use
  • 1.2.3. Testing Setting
  • 1.2.4. Throughput
  • 1.2.5. Regional
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Multiplex PCR Panel Testing Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising prevalence of respiratory and gastrointestinal infections
    • 3.2.1.2. Increasing demand for rapid syndromic testing in infectious disease diagnostics
    • 3.2.1.3. Continuous advancements in multiplexing and laboratory automation technologies
    • 3.2.1.4. Growing adoption of decentralized and point-of-care molecular diagnostic platforms
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost of multiplex PCR instruments and testing panel
    • 3.2.2.2. Limited reimbursement coverage and regulatory complexities for molecular diagnostic testing
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Multiplex PCR Panel Testing Market: Disease Application Business Analysis

• 4.1. Disease Application Market Share, 2025 & 2033
• 4.2. Disease Application Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Disease Application, 2021 to 2033 (USD Million)
• 4.4. Respiratory Panel
  • 4.4.1. Respiratory Panel Market, 2021 - 2033 (USD Million)
• 4.5. Gastrointestinal Panel
  • 4.5.1. Gastrointestinal Panel Market, 2021 - 2033 (USD Million)
• 4.6. Sexually Transmitted Infection (STI) Panel
  • 4.6.1. Sexually Transmitted Infection (STI) Panel Market, 2021 - 2033 (USD Million)
• 4.7. Bloodstream / Sepsis Panel
  • 4.7.1. Bloodstream / Sepsis Panel Market, 2021 - 2033 (USD Million)
• 4.8. Central Nervous System (CNS) Panel
  • 4.8.1. Central Nervous System (CNS) Panel Market, 2021 - 2033 (USD Million)
• 4.9. Tropical Disease Panel
  • 4.9.1. Tropical Disease Panel Market, 2021 - 2033 (USD Million)
• 4.10. Other Panel
  • 4.10.1. Other Panel Market, 2021 - 2033 (USD Million)

Chapter 5. Multiplex PCR Panel Testing Market: End Use Business Analysis

• 5.1. End Use Market Share, 2025 & 2033
• 5.2. End Use Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 5.4. Hospitals & Clinics
  • 5.4.1. Hospitals & Clinics Market, 2021 - 2033 (USD Million)
• 5.5. Diagnostic Laboratories (central labs)
  • 5.5.1. Diagnostic Laboratories (central labs) Market, 2021 - 2033 (USD Million)
• 5.6. Ambulatory Care Centers
  • 5.6.1. Ambulatory Care Centers Market, 2021 - 2033 (USD Million)
• 5.7. Academic & Research Institutes
  • 5.7.1. Academic & Research Institutes Market, 2021 - 2033 (USD Million)
• 5.8. Public Health Laboratories
  • 5.8.1. Public Health Laboratories Market, 2021 - 2033 (USD Million)
• 5.9. Physician Office Labs (POLs)
  • 5.9.1. Physician Office Labs (POLs) Market, 2021 - 2033 (USD Million)
• 5.10. Point-of-Care Settings
  • 5.10.1. Point-of-Care Settings Market, 2021 - 2033 (USD Million)

Chapter 6. Multiplex PCR Panel Testing Market: Testing Setting Business Analysis

• 6.1. Testing Setting Market Share, 2025 & 2033
• 6.2. Testing Setting Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Testing Setting, 2021 to 2033 (USD Million)
• 6.4. Centralized Laboratory Testing
  • 6.4.1. Centralized Laboratory Testing Market, 2021 - 2033 (USD Million)
• 6.5. Near-Patient Testing
  • 6.5.1. Near-Patient Testing Market, 2021 - 2033 (USD Million)
• 6.6. Others
  • 6.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. Multiplex PCR Panel Testing Market: Throughput Business Analysis

• 7.1. Throughput Market Share, 2025 & 2033
• 7.2. Throughput Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by Throughput 2021 to 2033 (USD Million)
• 7.4. Low-throughput systems (POC)
  • 7.4.1. Low-throughput systems (POC) 2021 - 2033 (USD Million)
• 7.5. Medium-throughput systems
  • 7.5.1. Medium-throughput systems 2021 - 2033 (USD Million)
• 7.6. High-throughput lab systems
  • 7.6.1. High-throughput lab systems 2021 - 2033 (USD Million)

Chapter 8. Multiplex PCR Panel Testing Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2025 & 2033
• 8.2. Regional Market Dashboard
• 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 8.4. North America
  • 8.4.1. North America Multiplex PCR Panel Testing Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Target Disease Prevalence
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Reimbursement Framework
    • 8.4.2.5. U.S. Multiplex PCR Panel Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Target Disease Prevalence
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Reimbursement Framework
    • 8.4.3.5. Canada Multiplex PCR Panel Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Target Disease Prevalence
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Reimbursement Framework
    • 8.4.4.5. Mexico Multiplex PCR Panel Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Europe
  • 8.5.1. Europe Multiplex PCR Panel Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Target Disease Prevalence
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Reimbursement Framework
    • 8.5.2.5. UK Multiplex PCR Panel Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Target Disease Prevalence
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Reimbursement Framework
    • 8.5.3.5. Germany Multiplex PCR Panel Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Target Disease Prevalence
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. Reimbursement Framework
    • 8.5.4.5. France Multiplex PCR Panel Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Target Disease Prevalence
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Reimbursement Framework
    • 8.5.5.5. Italy Multiplex PCR Panel Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Target Disease Prevalence
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Reimbursement Framework
    • 8.5.6.5. Spain Multiplex PCR Panel Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.7. Denmark
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Target Disease Prevalence
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Reimbursement Framework
    • 8.5.7.5. Denmark Multiplex PCR Panel Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.8. Sweden
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Target Disease Prevalence
    • 8.5.8.3. Regulatory Framework
    • 8.5.8.4. Reimbursement Framework
    • 8.5.8.5. Sweden Multiplex PCR Panel Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.9. Norway
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Target Disease Prevalence
    • 8.5.9.3. Regulatory Framework
    • 8.5.9.4. Reimbursement Framework
    • 8.5.9.5. Norway Multiplex PCR Panel Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific Multiplex PCR Panel Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Target Disease Prevalence
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Reimbursement Framework
    • 8.6.2.5. Japan Multiplex PCR Panel Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Target Disease Prevalence
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Reimbursement Framework
    • 8.6.3.5. China Multiplex PCR Panel Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Target Disease Prevalence
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. Reimbursement Framework
    • 8.6.4.5. India Multiplex PCR Panel Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.5. Australia
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Target Disease Prevalence
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Reimbursement Framework
    • 8.6.5.5. Australia Multiplex PCR Panel Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.6. South Korea
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Target Disease Prevalence
    • 8.6.6.3. Regulatory Framework
    • 8.6.6.4. Reimbursement Framework
    • 8.6.6.5. South Korea Multiplex PCR Panel Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Target Disease Prevalence
    • 8.6.7.3. Regulatory Framework
    • 8.6.7.4. Reimbursement Framework
    • 8.6.7.5. Thailand Multiplex PCR Panel Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America Multiplex PCR Panel Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Target Disease Prevalence
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. Reimbursement Framework
    • 8.7.2.5. Brazil Multiplex PCR Panel Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Target Disease Prevalence
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Reimbursement Framework
    • 8.7.3.5. Argentina Multiplex PCR Panel Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.8. Middle East and Africa
  • 8.8.1. Middle East and Africa Multiplex PCR Panel Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Target Disease Prevalence
    • 8.8.2.3. Regulatory Framework
    • 8.8.2.4. Reimbursement Framework
    • 8.8.2.5. South Africa Multiplex PCR Panel Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Target Disease Prevalence
    • 8.8.3.3. Regulatory Framework
    • 8.8.3.4. Reimbursement Framework
    • 8.8.3.5. Saudi Arabia Multiplex PCR Panel Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Target Disease Prevalence
    • 8.8.4.3. Regulatory Framework
    • 8.8.4.4. Reimbursement Framework
    • 8.8.4.5. UAE Multiplex PCR Panel Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Target Disease Prevalence
    • 8.8.5.3. Regulatory Framework
    • 8.8.5.4. Reimbursement Framework
    • 8.8.5.5. Kuwait Multiplex PCR Panel Testing Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Participant Overview
• 9.2. Company Market Position Analysis
• 9.3. Company Categorization
• 9.4. Strategy Mapping
• 9.5. Company Profiles/Listing
  • 9.5.1. F. Hoffmann-La Roche Ltd.
    • 9.5.1.1. Overview
    • 9.5.1.2. Financial Performance
    • 9.5.1.3. Product Benchmarking
    • 9.5.1.4. Strategic Initiatives
  • 9.5.2. bioMerieux SA
    • 9.5.2.1. Overview
    • 9.5.2.2. Financial Performance
    • 9.5.2.3. Product Benchmarking
    • 9.5.2.4. Strategic Initiatives
  • 9.5.3. QIAGEN N.V.
    • 9.5.3.1. Overview
    • 9.5.3.2. Financial Performance
    • 9.5.3.3. Product Benchmarking
    • 9.5.3.4. Strategic Initiatives
  • 9.5.4. Thermo Fisher Scientific Inc.
    • 9.5.4.1. Overview
    • 9.5.4.2. Financial Performance
    • 9.5.4.3. Product Benchmarking
    • 9.5.4.4. Strategic Initiatives
  • 9.5.5. DiaSorin S.p.A
    • 9.5.5.1. Overview
    • 9.5.5.2. Financial Performance
    • 9.5.5.3. Product Benchmarking
    • 9.5.5.4. Strategic Initiatives
  • 9.5.6. Abbott
    • 9.5.6.1. Overview
    • 9.5.6.2. Financial Performance
    • 9.5.6.3. Product Benchmarking
    • 9.5.6.4. Strategic Initiatives
  • 9.5.7. BD
    • 9.5.7.1. Overview
    • 9.5.7.2. Financial Performance
    • 9.5.7.3. Product Benchmarking
    • 9.5.7.4. Strategic Initiatives
  • 9.5.8. AusDiagnostics
    • 9.5.8.1. Overview
    • 9.5.8.2. Financial Performance
    • 9.5.8.3. Product Benchmarking
    • 9.5.8.4. Strategic Initiatives
  • 9.5.9. Bio-Rad Laboratories Inc.
    • 9.5.9.1. Overview
    • 9.5.9.2. Financial Performance
    • 9.5.9.3. Product Benchmarking
    • 9.5.9.4. Strategic Initiatives
  • 9.5.10. Cepheid
    • 9.5.10.1. Overview
    • 9.5.10.2. Financial Performance
    • 9.5.10.3. Product Benchmarking
    • 9.5.10.4. Strategic Initiatives